• About us
• Contact

Advertisement

Product › Details

cardiovascular drug

	Next higher product group	pharmaceutical
	Status	1998-01-01 sales existent

Record changed: 2024-09-02

Advertisement

More documents for cardiovascular drug

• [1] Idorsia Ltd.. (12/20/24). "Press Release: Idorsia Provides Update on the Exclusive Negotiations for the Global Rights to Aprocitentan". Allschwil....
• [2] Idorsia Ltd.. (11/27/24). "Press Release: Idorsia Enters into Exclusive Negotiations for Global Rights to Aprocitentan". Allschwil....
• [3] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
• [4] Idorsia Ltd.. (7/1/24). "Press Release: Idorsia’s Jeraygo (aprocitentan) Approved in Europe as First and Only ERA for the Treatment of Resistant Hypertension". Allschwil....
• [5] Evotec SE. (6/24/24). "Press Release: beLAB1407 to Develop Novel Approach for Cardiovascular Diseases". Hamburg....
• [6] Forbion Capital Partners. (6/18/24). "Press Release: Forbion Co-leads $190 Million Financing of Marea Therapeutics". Naarden....
• [7] Marea Therapeutics. (6/18/24). "Press Release: Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases". South San Francisco, CA....
• [8] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
• [9] Idorsia Ltd.. (3/20/24). "Press Release: US FDA Approves Idorsia’s Once-daily Tryvio (aprocitentan) – the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with other Antihy...
• [10] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.